Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Research & Development (2016 - 2025)

Historic Research & Development for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $674362.0.

  • Iradimed's Research & Development rose 545.69% to $674362.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 570.29%. This contributed to the annual value of $2.8 million for FY2024, which is 94.68% down from last year.
  • According to the latest figures from Q3 2025, Iradimed's Research & Development is $674362.0, which was up 545.69% from $877362.0 recorded in Q2 2025.
  • In the past 5 years, Iradimed's Research & Development registered a high of $3.0 million during Q1 2023, and its lowest value of $452555.0 during Q3 2023.
  • Over the past 5 years, Iradimed's median Research & Development value was $624245.0 (recorded in 2025), while the average stood at $750294.7.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 47792.43% in 2023, then plummeted by 7263.31% in 2024.
  • Quarter analysis of 5 years shows Iradimed's Research & Development stood at $494851.0 in 2021, then increased by 22.21% to $604744.0 in 2022, then increased by 7.56% to $650435.0 in 2023, then dropped by 12.37% to $569993.0 in 2024, then rose by 18.31% to $674362.0 in 2025.
  • Its Research & Development was $674362.0 in Q3 2025, compared to $877362.0 in Q2 2025 and $624245.0 in Q1 2025.